For example, combination treatment involving RFA and sunitinib has been shown to activate the local tumour-specific antigen immune response, increase the frequency of CD8+ T cells, memory CD8+ T cells, and dendritic cells, and decrease the frequency of regulatory T cells. The gene discussed is CD8A; the disease is neoplasm.